IL315702A - Deuterated pyrrole inhibitory analogs of ERK, their synthesis and their intermediates - Google Patents

Deuterated pyrrole inhibitory analogs of ERK, their synthesis and their intermediates

Info

Publication number
IL315702A
IL315702A IL315702A IL31570224A IL315702A IL 315702 A IL315702 A IL 315702A IL 315702 A IL315702 A IL 315702A IL 31570224 A IL31570224 A IL 31570224A IL 315702 A IL315702 A IL 315702A
Authority
IL
Israel
Prior art keywords
formula
compound
deuterium
pharmaceutical composition
reacting
Prior art date
Application number
IL315702A
Other languages
English (en)
Hebrew (he)
Inventor
Gary Decrescenzo
Martin Teresk
Original Assignee
Biomed Valley Discoveries Inc
Gary Decrescenzo
Martin Teresk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries Inc, Gary Decrescenzo, Martin Teresk filed Critical Biomed Valley Discoveries Inc
Publication of IL315702A publication Critical patent/IL315702A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL315702A 2022-03-24 2023-03-24 Deuterated pyrrole inhibitory analogs of ERK, their synthesis and their intermediates IL315702A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263323221P 2022-03-24 2022-03-24
PCT/US2023/064908 WO2023183905A2 (en) 2022-03-24 2023-03-24 Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto

Publications (1)

Publication Number Publication Date
IL315702A true IL315702A (en) 2024-11-01

Family

ID=88102044

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315702A IL315702A (en) 2022-03-24 2023-03-24 Deuterated pyrrole inhibitory analogs of ERK, their synthesis and their intermediates

Country Status (10)

Country Link
US (1) US20250026733A1 (enExample)
EP (1) EP4499623A2 (enExample)
JP (1) JP2025509969A (enExample)
CN (1) CN119212985A (enExample)
AU (1) AU2023238106A1 (enExample)
CA (1) CA3245978A1 (enExample)
IL (1) IL315702A (enExample)
MX (1) MX2024011415A (enExample)
TW (1) TW202400572A (enExample)
WO (1) WO2023183905A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250391A1 (en) * 2024-05-28 2025-12-04 Biomed Valley Discoveries, Inc. Compositions and methods for solid forms of ulixertinib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84930C2 (ru) * 2004-05-14 2008-12-10 Вертекс Фармасьютикалс Инкорпорейтед Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
US9227969B2 (en) * 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
HK1244274A1 (zh) * 2015-01-30 2018-08-03 生物医学谷探索股份有限公司 C21h22ci2n4o2的晶型

Also Published As

Publication number Publication date
JP2025509969A (ja) 2025-04-11
CA3245978A1 (en) 2023-09-28
WO2023183905A3 (en) 2023-10-26
TW202400572A (zh) 2024-01-01
US20250026733A1 (en) 2025-01-23
WO2023183905A2 (en) 2023-09-28
EP4499623A2 (en) 2025-02-05
AU2023238106A1 (en) 2024-09-26
CN119212985A (zh) 2024-12-27
MX2024011415A (es) 2024-09-24

Similar Documents

Publication Publication Date Title
USRE49500E1 (en) Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
JP2022071072A (ja) （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラ－ヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミドの結晶形、その調製、及びその使用
TWI405761B (zh) 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚
JP2023030076A (ja) Ｆｘｒアゴニストの固体形態
US10568965B2 (en) Aminopyrimidine inhibitors of tyrosine kinase
IL191776A (en) Carbonylamino pyrrolopyrazole compounds , pharmaceutical compositions comprising them and use of the compounds in the preparation of medicaments
CN111386260A (zh) 磺酰胺化合物及其用途
CA2876306A1 (en) Deuterated derivatives of ruxolitinib
CN102459270A (zh) Janus激酶3的哌啶抑制剂
CN104507946A (zh) 氘代依鲁替尼
KR20100050466A (ko) 섬유증 저해제로서의 치환된 ｎ-아릴 피리디논
US11534434B2 (en) Xanomeline derivatives and methods for treating neurological disorders
JP2010508363A (ja) ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物
EP3126331A1 (en) Oxindole inhibitors of tyrosine kinase
EP2470542A2 (en) Preparation of sitagliptin and salts thereof
US20250026733A1 (en) Deuterated analogs of pyrole inhibitors of erk, synthesis thereof and intermediates thereto
CN112469473A (zh) 作为magl抑制剂的杂环螺环化合物
JP2021529819A (ja) Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体
HK40118078A (zh) Erk的吡咯抑制剂的氘代类似物、其合成及其中间体
CN107964012B (zh) 作为parp抑制剂的化合物及其用途
US20100093758A1 (en) Pyridine sulfonamide modulators of endothelin-a receptor
TWI692476B (zh) 環丁基-咪唑啶酮化合物
JP2026505525A (ja) ピロロピリジン誘導体の結晶形
HK40044064A (en) Heterocyclic spiro compounds as magl inhibitors
WO2007039581A1 (en) Imidazolyl-substituted diazabenzophenone compounds